SFRP2+ CAFs Hinder Abscopal Effect from Combined Radiotherapy and Immunotherapy by Forming a Hostile Perivascular Niche [II]
RNA-seq (gene expression) · mouse · 15 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 15 samples: 5 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE263386_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1097255 and SRA study SRP500164. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 15 samples.
How we read this: 5 replicated groups read from 15 sample titles; they account for 15 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8190697 LLC1-sgLkb1, RT, 1 LLC1-sgLkb1, RT,
- GSM8190698 LLC1-sgLkb1, RT, 4 LLC1-sgLkb1, RT,
- GSM8190699 LLC1-sgLkb1, RT, 5 LLC1-sgLkb1, RT,
- GSM8190700 LLC1, RI, 1 LLC1, RI,
- GSM8190701 LLC1, RI, 2 LLC1, RI,
- GSM8190702 LLC1, RI, 3 LLC1, RI,
- GSM8190703 LLC1, ICI, 1 LLC1, ICI,
- GSM8190704 LLC1, ICI, 2 LLC1, ICI,
- GSM8190705 LLC1, ICI, 3 LLC1, ICI,
- GSM8190706 LLC1-sgLkb1, ICI, 1 LLC1-sgLkb1, ICI,
- GSM8190707 LLC1-sgLkb1, ICI, 2 LLC1-sgLkb1, ICI,
- GSM8190708 LLC1-sgLkb1, ICI, 3 LLC1-sgLkb1, ICI,
- GSM8190709 LLC1-sgLkb1, RI, 1 LLC1-sgLkb1, RI,
- GSM8190710 LLC1-sgLkb1, RI, 2 LLC1-sgLkb1, RI,
- GSM8190711 LLC1-sgLkb1, RI, 3 LLC1-sgLkb1, RI,
- GSE267158 Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy 48 samples shares immunotherapy, radiotherapy
- GSE325822 Bimodal Imaging-Guided Temporal Optimization of Combined Chemotherapy and DC Vaccine Immunotherapy 45 samples shares immunotherapy, combined
- GSE264527 Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with combined SOS1 and MEK Inhibition for Improved Immunotherapy Response 21 samples shares immunotherapy, combined
- GSE280080 Radiotherapy synergizes with AAV-based immunotherapy to program local and systemic antitumor immunity 15 samples shares immunotherapy, radiotherapy
- GSE249630 Modeling T cell temporal response to cancer immunotherapy rationalize development of combinatorial treatments protocols 1372 samples shares immunotherapy
- GSE229916 Pericytes and perivascular fibroblasts contribute to central nervous system fibrosis in a region dependent manner 832 samples shares perivascular
- GSE215960 Subclonal evolution revealed by single-cell profiles of expressed mutations identifies adaptation mechanisms to immunotherapy in melanoma [scRNA-seq] 192 samples shares immunotherapy
- GSE302715 A tumor-associated macrophage-targeted immunocytokine leveraging T and NK cell synergy for potent cancer immunotherapy [scRNA-seq] 187 samples shares immunotherapy
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.